Relatlimab, an Immune Checkpoint Inhibitor that Blocks LAG-3, the Latest Drug to be Added to the Arsenal of Systemic Therapies for Melanoma: What Does a Surgical Oncologist Need to Know? | Ann Surg Oncol;31(1): 1-3, 2024 01. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Relatlimab, an Immune Checkpoint Inhibitor that Blocks LAG-3, the Latest Drug to be Added to the Arsenal of Systemic Therapies for Melanoma: What Does a Surgical Oncologist Need to Know?

van Akkooi, Alexander C J.

Affiliation

van Akkooi ACJ; Melanoma Institute Australia, Sydney, NSW, Australia. alexander.vanakkooi@melanoma.org.au.

Ann Surg Oncol ; 31(1): 1-3, 2024 01.

Article in En | MEDLINE | ID: mdl-37843663

Subject(s)

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oncologists / Melanoma Limits: Humans Language: En Journal: Ann Surg Oncol Journal subject: NEOPLASIAS Year: 2024 Document type: Article Affiliation country: Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oncologists / Melanoma Limits: Humans Language: En Journal: Ann Surg Oncol Journal subject: NEOPLASIAS Year: 2024 Document type: Article Affiliation country: Country of publication: